Author Correction: Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril

N. FERRI, A. CORSINI, R. PONTREMOLI

Department of Medicine, University of Padua, Padua, Italy


After publication, the authors applied some corrections to the text:

- The section “Clinical Pharmacology of Lercanidipine” has been corrected into “Clinical Pharmacology of Lercanidipine”

- The Legend of Figure 2 has been corrected as follows: Ca T-type channels vs. Ca L-type channels selectivity ratio. LAC, lacidipine, AML, amlodipine; MIB, mibefradil; LER, lercanidipine; *p<0.05, **p<0.01 vs. LAC (low concentrations); †p<0.01 LAC vs. all other CCBs (high concentrations). Source: Modified from 25.


There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.